15 Biotech Stocks Wall Street Analysts Say Are Too Cheap
Investors have begun to flirt with a sector that has been distinctly out of favor for more than two years.
Stay updated with breaking news from Altimmune. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investors have begun to flirt with a sector that has been distinctly out of favor for more than two years.
Altimmune, Inc. (NASDAQ:ALT – Get Rating) has earned an average recommendation of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month price objective among brokerages […]
GAITHERSBURG, Md., May 31, 2023 -- Altimmune, Inc. , a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be... | May 31, 2023
Redefining and Executing Dual Agonist Enterohormone Therapies for Obesity Sarah K. Browne, MD Vice President, Clinical Development ... | May 31, 2023
Sectoral Asset Management Inc. grew its holdings in Altimmune, Inc. (NASDAQ:ALT – Get Rating) by 27.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 342,500 shares of the company’s stock after acquiring an additional 73,400 shares during the period. Sectoral Asset Management […]